Leduc-Pessah Heather, Weilinger Nicholas L, Fan Churmy Y, Burma Nicole E, Thompson Roger J, Trang Tuan
Departments of Comparative Biology & Experimental Medicine, and Physiology & Pharmacology.
Hotchkiss Brain Institute, and.
J Neurosci. 2017 Oct 18;37(42):10154-10172. doi: 10.1523/JNEUROSCI.0852-17.2017. Epub 2017 Sep 18.
Tolerance to the analgesic effects of opioids is a major problem in chronic pain management. Microglia are implicated in opioid tolerance, but the core mechanisms regulating their response to opioids remain obscure. By selectively ablating microglia in the spinal cord using a saporin-conjugated antibody to Mac1, we demonstrate a causal role for microglia in the development, but not maintenance, of morphine tolerance in male rats. Increased P2X7 receptor (P2X7R) activity is a cardinal feature of microglial activation, and in this study we found that morphine potentiates P2X7R-mediated Ca responses in resident spinal microglia acutely isolated from morphine tolerant rats. The increased P2X7R function was blocked in cultured microglia by PP2, a Src family protein tyrosine kinase inhibitor. We identified Src family kinase activation mediated by μ-receptors as a key mechanistic step required for morphine potentiation of P2X7R function. Furthermore, we show by site-directed mutagenesis that tyrosine (Y) within the P2X7R C-terminus is differentially modulated by repeated morphine treatment and has no bearing on normal P2X7R function. Intrathecal administration of a palmitoylated peptide corresponding to the Y site suppressed morphine-induced microglial reactivity and preserved the antinociceptive effects of morphine in male rats. Thus, site-specific regulation of P2X7R function mediated by Y is a novel cellular determinant of the microglial response to morphine that critically underlies the development of morphine analgesic tolerance. Controlling pain is one of the most difficult challenges in medicine and its management is a requirement of a large diversity of illnesses. Although morphine and other opioids offer dramatic and impressive relief of pain, their impact is truncated by loss of efficacy (analgesic tolerance). Understanding why this occurs and how to prevent it are of critical importance in improving pain therapies. We uncovered a novel site (Y) within the P2X7 receptor that can be targeted to blunt the development of morphine analgesic tolerance, without affecting normal P2X7 receptor function. Our findings provide a critical missing mechanistic piece, site-specific modulation by Y, that unifies P2X7R function to the activation of spinal microglia and the development of morphine tolerance.
对阿片类药物镇痛作用产生耐受是慢性疼痛管理中的一个主要问题。小胶质细胞与阿片类药物耐受有关,但其调节对阿片类药物反应的核心机制仍不清楚。通过使用与Mac1结合的皂草素抗体选择性地消融脊髓中的小胶质细胞,我们证明了小胶质细胞在雄性大鼠吗啡耐受的形成而非维持中起因果作用。P2X7受体(P2X7R)活性增加是小胶质细胞激活的一个主要特征,在本研究中我们发现吗啡可增强急性分离自吗啡耐受大鼠的脊髓常驻小胶质细胞中P2X7R介导的钙反应。PP2(一种Src家族蛋白酪氨酸激酶抑制剂)可阻断培养的小胶质细胞中P2X7R功能的增强。我们确定μ受体介导的Src家族激酶激活是吗啡增强P2X7R功能所需的关键机制步骤。此外,我们通过定点诱变表明,P2X7R C末端的酪氨酸(Y)受重复吗啡治疗的差异调节,且与正常P2X7R功能无关。鞘内注射与Y位点对应的棕榈酰化肽可抑制吗啡诱导的小胶质细胞反应性,并保留吗啡对雄性大鼠的镇痛作用。因此,由Y介导的P2X7R功能的位点特异性调节是小胶质细胞对吗啡反应的一种新的细胞决定因素,它是吗啡镇痛耐受形成的关键基础。控制疼痛是医学中最困难的挑战之一,对多种疾病的治疗都需要对疼痛进行管理。尽管吗啡和其他阿片类药物能显著缓解疼痛,但其效果会因疗效丧失(镇痛耐受)而受到影响。了解其发生原因及如何预防对改善疼痛治疗至关重要。我们在P2X7受体中发现了一个新位点(Y),可针对该位点来减弱吗啡镇痛耐受的形成,而不影响正常P2X7受体功能。我们的研究结果提供了一个关键的缺失机制环节,即Y的位点特异性调节,它将P2X7R功能与脊髓小胶质细胞的激活及吗啡耐受的形成联系起来。